title: A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML.
authors.affiliation: Cancer Therapeutics Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.|The Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia.
authors.forename: L M
authors.initials: LM
authors.lastname: Kats
authors.affiliation: Cancer Therapeutics Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
authors.forename: S J
authors.initials: SJ
authors.lastname: Vervoort
authors.affiliation: Cancer Therapeutics Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
authors.forename: R
authors.initials: R
authors.lastname: Cole
authors.affiliation: Cancer Therapeutics Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
authors.forename: A J
authors.initials: AJ
authors.lastname: Rogers
authors.affiliation: Cancer Therapeutics Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.|The Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia.|Monash Haematology, Monash Health and School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia.
authors.forename: G P
authors.initials: GP
authors.lastname: Gregory
authors.affiliation: Cancer Therapeutics Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
authors.forename: E
authors.initials: E
authors.lastname: Vidacs
authors.affiliation: The Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia.|Bioinformatics Core, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
authors.forename: J
authors.initials: J
authors.lastname: Li
authors.affiliation: Agios Pharmaceuticals, Cambridge, MA, USA.
authors.forename: R
authors.initials: R
authors.lastname: Nagaraja
authors.affiliation: Agios Pharmaceuticals, Cambridge, MA, USA.
authors.forename: K E
authors.initials: KE
authors.lastname: Yen
authors.affiliation: Cancer Therapeutics Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.|The Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia.
authors.forename: R W
authors.initials: RW
authors.lastname: Johnstone
mesh_terms: D000631:Aminopyridines / Q000494:pharmacology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007521:Isocitrate Dehydrogenase / Q000037:antagonists & inhibitors* / Q000235:genetics; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D009154:Mutation; D010597:Pharmacogenetics; D014227:Triazines / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000631:Aminopyridines; D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D014227:Triazines; C000605269:enasidenib; C538784:IDH2 protein, human; D007521:Isocitrate Dehydrogenase